<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912011</url>
  </required_header>
  <id_info>
    <org_study_id>0012/100/2020</org_study_id>
    <nct_id>NCT04912011</nct_id>
  </id_info>
  <brief_title>Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.</brief_title>
  <acronym>SpiroCOVID19</acronym>
  <official_title>The Use of a Mineralocorticoid Receptor Antagonist (Spironolactone) in the Treatment of Pulmonary Fibrosis Associated With SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pomeranian Medical University Szczecin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pomeranian Medical University Szczecin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019 SARS-CoV-2 virus appeared in the world, mainly appearing as an acute&#xD;
      infection of the lower respiratory tract. In March 2020, the World Health Organization (WHO)&#xD;
      announced a pandemic in relation to the disease caused by the SARS-CoV-2 virus, known as&#xD;
      COronaVIrus Disease 2019 (COVID-19). Since then, the efforts of scientists from around the&#xD;
      world have focused on finding the right treatment and vaccine for the new disease. COVID-19&#xD;
      has spread rapidly in a few months, affecting patients in all ages. The disease has a varied&#xD;
      course, patients can be 80% asymptomatic, but many develop respiratory failure, complicated&#xD;
      by sepsis and ultimately death. One of the possible complications associated with COVID-19&#xD;
      lung involvement is pulmonary fibrosis, leading to chronic breathing difficulties and&#xD;
      prolonged disability. No specific mechanisms leading to this phenomenon have been identified&#xD;
      in COVID-19, but some information is derived from previous studies on the SARS and MERS&#xD;
      epidemic. There have been several reports that the use of spironolactone may be important in&#xD;
      preventing pulmonary fibrosis.&#xD;
&#xD;
      The aim of the study is to evaluate the effectiveness of intravenous form of&#xD;
      mineralocorticoid receptor antagonist canrenoate potassium (an aldosterone antagonist of the&#xD;
      spirolactone group) in the treatment of COVID-19-associated pulmonary fibrosis based on the&#xD;
      mechanisms of the immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of invasive mechanical ventilation via endotracheal intubation or tracheotomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Passive oxygen therapy</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of passive oxygen therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU LOS</measure>
    <time_frame>30 days</time_frame>
    <description>Intensive Care Unit length of stay (LOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital LOS</measure>
    <time_frame>90 days</time_frame>
    <description>Total hospital length of stay (LOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT</measure>
    <time_frame>90 days</time_frame>
    <description>Assessment of the dynamics of recovery of changes in chest CT at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung ultrasound_7</measure>
    <time_frame>7 days</time_frame>
    <description>Assessment of the dynamics of recovery of changes in lung ultrasound at 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung ultrasound_30</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of the dynamics of recovery of changes in lung ultrasound at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality_30</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of mortality at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality_90</measure>
    <time_frame>90 days</time_frame>
    <description>Assessment of mortality at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1β level change.</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of the degree of change of the level of pro-inflammatory cytokine IL-1β.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-2 level change.</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of the degree of change of the level of pro-inflammatory cytokine IL-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 level change.</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of the degree of change of the level of pro-inflammatory cytokine IL-6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-33 level change.</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of the degree of change of the level of pro-inflammatory cytokine IL-33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNFα level change.</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of the degree of change of the level of pro-inflammatory cytokine TNFα.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT</measure>
    <time_frame>30 days</time_frame>
    <description>Six minute walk test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Canrenoate potassium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 200 mg of potassium Canrenoate potassium dissolved in 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 100 ml of 0.9% sodium chloride intravenously twice a day for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canrenoate Potassium</intervention_name>
    <description>Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.</description>
    <arm_group_label>Canrenoate potassium</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both sexes, 18-90 years of age.&#xD;
&#xD;
          2. Patient requiring oxygen therapy, SpO2 &lt;94%.&#xD;
&#xD;
          3. Confirmed COVID-19 infection.&#xD;
&#xD;
          4. At least one risk factor for increased mortality in the course of COVID-19: currently&#xD;
             published in the literature e.g. smoking, hypertension, diabetes, cardiovascular&#xD;
             disease.&#xD;
&#xD;
          5. Documented informed consent according to ICH-GCP and national regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic bronchitis, emphysema, interstitial lung disease, or other history of lung&#xD;
             disease.&#xD;
&#xD;
          2. Contraindications to the use of spironolactone.&#xD;
&#xD;
          3. Hypersensitivity to spironolactone or any of the excipients.&#xD;
&#xD;
          4. Pregnant patients (pregnancy test will be performed in every patient of reproductive&#xD;
             age) and during lactation.&#xD;
&#xD;
          5. Patients with mental illness or dementia who are unable to give informed consent to&#xD;
             the examination.&#xD;
&#xD;
          6. ARDS caused by another viral infection (SARS-CoV-2 negative).&#xD;
&#xD;
          7. ARDS from other causes/trauma.&#xD;
&#xD;
          8. Ionic disorders: hyperkalemia, hyponatraemia.&#xD;
&#xD;
          9. Adrenal crisis.&#xD;
&#xD;
         10. Acute and chronic renal failure, creatinine clearance less than 30 ml/min.&#xD;
&#xD;
         11. Anuria.&#xD;
&#xD;
         12. Porphyria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarzyna L Kotfis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pomeranian Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna L Kotfis, MD, PhD</last_name>
    <phone>0048602449202</phone>
    <email>katarzyna.kotfis@pum.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pomeranian Medical University</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna L Kotfis, MD</last_name>
      <phone>0048914661144</phone>
      <email>katarzyna.kotfis@pum.edu.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Lechowicz K, Drożdżal S, Machaj F, Rosik J, Szostak B, Zegan-Barańska M, Biernawska J, Dabrowski W, Rotter I, Kotfis K. COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. J Clin Med. 2020 Jun 19;9(6). pii: E1917. doi: 10.3390/jcm9061917. Review.</citation>
    <PMID>32575380</PMID>
  </reference>
  <reference>
    <citation>Kotfis K, Lechowicz K, Drożdżal S, Niedźwiedzka-Rystwej P, Wojdacz TK, Grywalska E, Biernawska J, Wiśniewska M, Parczewski M. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021 Jan 17;14(1). pii: 71. doi: 10.3390/ph14010071. Review.</citation>
    <PMID>33477294</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pomeranian Medical University Szczecin</investigator_affiliation>
    <investigator_full_name>Katarzyna Kotfis</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>spironolactone</keyword>
  <keyword>pneumonia</keyword>
  <keyword>fibrosis</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>potassium canrenoate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canrenoic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

